Ducera 2022 Info?
Given the slow down of RX, seems like they've become more generalist-focused. Can anyone chime in to the comp (did they bump up to 95k/110k yet?), exit opps (given the lack of RX-related deal flow)? Anything else I'm missing like hours?
Would be great to hear any thoughts as well on their M&A/Strategic Advisory work. I know they punch above their weight for RX mandates. Is their M&A work mostly middle market given the firm is mostly RX-focused and may not have as much recognition in the M&A area?
Inventore nam quibusdam ea velit aut. Laudantium maxime laborum provident. Eveniet non quis sunt reiciendis nobis similique.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...